Assessment of Rituximab's Immunomodulatory Synovial Effects (The ARISE Study)

University of California San Diego

Status and phase: Completed; Phase 2

Conditions: Rheumatoid Arthritis

Treatments: Drug: rituximab

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00147966

041569

Details and patient eligibility

About

Using repeated arthroscopic biopsies of patients with rheumatoid arthritis, the researchers will assess changes in the immune response that occur as a result of treatment with rituximab.

Full description

Using repeated arthroscopic biopsies of patients with rheumatoid arthritis, the researchers will assess changes in the immune response that occur after treatment with rituximab.

Enrollment: 24 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Active rheumatoid arthritis
• Use of concomitant methotrexate

Exclusion criteria

• Use of disease-modifying anti-rheumatic drugs (DMARDs)/biologics other than methotrexate
• Serious medical conditions that would preclude the use of the treating agent

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

24 participants in 1 patient group

ritxumab

Experimental group

Description:

all patients get treatment

Treatment:

Drug: rituximab